Description
DexCom’s Market Expansion Move: Will Targeting Non-Insulin Users Pay Off?
DexCom Inc., a leader in continuous glucose monitoring (CGM) systems, reported significant developments in its second quarter of 2025 earnings call. Highlighting a strong quarter, DexCom achieved a 15% organic revenue growth from the previous year, totaling $1.16 billion. This growth was predominantly driven by increased demand for CGM in both the U.S. and international markets, coupled with expanded coverage for type 2 non-insulin diabetes patients.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
